nodes	percent_of_prediction	percent_of_DWPC	metapath
Docetaxel—head and neck cancer—skin cancer	0.302	0.532	CtDrD
Docetaxel—melanoma—skin cancer	0.265	0.468	CtDrD
Docetaxel—ABCC1—Vemurafenib—skin cancer	0.0438	0.172	CbGbCtD
Docetaxel—ABCG2—Vismodegib—skin cancer	0.0371	0.145	CbGbCtD
Docetaxel—ABCG2—Vemurafenib—skin cancer	0.0293	0.115	CbGbCtD
Docetaxel—ABCC1—Dactinomycin—skin cancer	0.0291	0.114	CbGbCtD
Docetaxel—SLC22A7—Fluorouracil—skin cancer	0.0251	0.0983	CbGbCtD
Docetaxel—ABCG2—Dactinomycin—skin cancer	0.0195	0.0764	CbGbCtD
Docetaxel—ABCB1—Vismodegib—skin cancer	0.0134	0.0525	CbGbCtD
Docetaxel—ABCG2—Fluorouracil—skin cancer	0.0132	0.0517	CbGbCtD
Docetaxel—CYP3A4—Imiquimod—skin cancer	0.0116	0.0453	CbGbCtD
Docetaxel—CYP3A4—Temozolomide—skin cancer	0.0116	0.0453	CbGbCtD
Docetaxel—CYP3A4—Vismodegib—skin cancer	0.00802	0.0314	CbGbCtD
Docetaxel—ABCB1—Dactinomycin—skin cancer	0.00703	0.0276	CbGbCtD
Docetaxel—CYP3A4—Vemurafenib—skin cancer	0.00634	0.0248	CbGbCtD
Docetaxel—MAP4—hair follicle—skin cancer	0.00143	0.0353	CbGeAlD
Docetaxel—MAP2—nerve—skin cancer	0.00134	0.0332	CbGeAlD
Docetaxel—KIF11—Sorafenib—Vismodegib—skin cancer	0.00131	0.56	CbGdCrCtD
Docetaxel—KIF11—mammalian vulva—skin cancer	0.00123	0.0304	CbGeAlD
Docetaxel—KIF11—female reproductive system—skin cancer	0.00105	0.026	CbGeAlD
Docetaxel—GHRHR—head—skin cancer	0.00103	0.0255	CbGeAlD
Docetaxel—TUBB4B—skin epidermis—skin cancer	0.000949	0.0235	CbGeAlD
Docetaxel—BCL2—neck—skin cancer	0.00087	0.0215	CbGeAlD
Docetaxel—TUBB—hair follicle—skin cancer	0.000794	0.0197	CbGeAlD
Docetaxel—MAP2—nipple—skin cancer	0.000762	0.0189	CbGeAlD
Docetaxel—MAP2—neck—skin cancer	0.000754	0.0187	CbGeAlD
Docetaxel—TUBB4B—Sorafenib—Vismodegib—skin cancer	0.000691	0.294	CbGdCrCtD
Docetaxel—MAP4—connective tissue—skin cancer	0.000686	0.017	CbGeAlD
Docetaxel—TUBB3—connective tissue—skin cancer	0.000686	0.017	CbGeAlD
Docetaxel—TUBB4B—hair follicle—skin cancer	0.000677	0.0168	CbGeAlD
Docetaxel—BCL2—connective tissue—skin cancer	0.000624	0.0154	CbGeAlD
Docetaxel—MAP4—skin of body—skin cancer	0.000619	0.0153	CbGeAlD
Docetaxel—NR1I2—head—skin cancer	0.000618	0.0153	CbGeAlD
Docetaxel—KIF11—lymph node—skin cancer	0.000614	0.0152	CbGeAlD
Docetaxel—TUBB8—head—skin cancer	0.000592	0.0147	CbGeAlD
Docetaxel—BCL2—epithelium—skin cancer	0.000592	0.0147	CbGeAlD
Docetaxel—TUBB2B—nipple—skin cancer	0.000569	0.0141	CbGeAlD
Docetaxel—BCL2—skin of body—skin cancer	0.000563	0.0139	CbGeAlD
Docetaxel—TUBB—nipple—skin cancer	0.000538	0.0133	CbGeAlD
Docetaxel—CYP1B1—hair follicle—skin cancer	0.000536	0.0133	CbGeAlD
Docetaxel—TUBB2A—nipple—skin cancer	0.000535	0.0133	CbGeAlD
Docetaxel—TUBB6—nipple—skin cancer	0.000528	0.0131	CbGeAlD
Docetaxel—EGFR—mammalian vulva—skin cancer	0.000507	0.0126	CbGeAlD
Docetaxel—MAP4—lymphoid tissue—skin cancer	0.000502	0.0124	CbGeAlD
Docetaxel—TUBB3—lymphoid tissue—skin cancer	0.000502	0.0124	CbGeAlD
Docetaxel—MAP4—female reproductive system—skin cancer	0.000484	0.012	CbGeAlD
Docetaxel—ABCC1—hair follicle—skin cancer	0.000482	0.0119	CbGeAlD
Docetaxel—ABCC10—nipple—skin cancer	0.000462	0.0115	CbGeAlD
Docetaxel—TUBB4B—nipple—skin cancer	0.000459	0.0114	CbGeAlD
Docetaxel—BCL2—lymphoid tissue—skin cancer	0.000456	0.0113	CbGeAlD
Docetaxel—MAP2—mammalian vulva—skin cancer	0.000445	0.011	CbGeAlD
Docetaxel—BCL2—female reproductive system—skin cancer	0.00044	0.0109	CbGeAlD
Docetaxel—TUBB4A—connective tissue—skin cancer	0.000417	0.0103	CbGeAlD
Docetaxel—TUBB3—head—skin cancer	0.000404	0.01	CbGeAlD
Docetaxel—MAP4—head—skin cancer	0.000404	0.01	CbGeAlD
Docetaxel—TUBB2B—connective tissue—skin cancer	0.000403	0.00999	CbGeAlD
Docetaxel—TUBB1—head—skin cancer	0.000395	0.00979	CbGeAlD
Docetaxel—MAP2—female reproductive system—skin cancer	0.000381	0.00943	CbGeAlD
Docetaxel—TUBB2A—connective tissue—skin cancer	0.00038	0.00941	CbGeAlD
Docetaxel—TUBB4A—skin of body—skin cancer	0.000377	0.00934	CbGeAlD
Docetaxel—BCL2—head—skin cancer	0.000367	0.0091	CbGeAlD
Docetaxel—MAPT—lymph node—skin cancer	0.00036	0.00891	CbGeAlD
Docetaxel—TUBB6—epithelium—skin cancer	0.000356	0.00881	CbGeAlD
Docetaxel—TUBB6—Sorafenib—Vismodegib—skin cancer	0.000344	0.147	CbGdCrCtD
Docetaxel—TUBB2A—skin of body—skin cancer	0.000343	0.00849	CbGeAlD
Docetaxel—TUBB6—skin of body—skin cancer	0.000338	0.00838	CbGeAlD
Docetaxel—TUBB2B—mammalian vulva—skin cancer	0.000332	0.00823	CbGeAlD
Docetaxel—ABCC1—nipple—skin cancer	0.000327	0.0081	CbGeAlD
Docetaxel—TUBB4B—connective tissue—skin cancer	0.000326	0.00806	CbGeAlD
Docetaxel—MAP2—head—skin cancer	0.000318	0.00788	CbGeAlD
Docetaxel—TUBB—mammalian vulva—skin cancer	0.000314	0.00779	CbGeAlD
Docetaxel—TUBB2A—mammalian vulva—skin cancer	0.000313	0.00775	CbGeAlD
Docetaxel—TUBB6—mammalian vulva—skin cancer	0.000308	0.00764	CbGeAlD
Docetaxel—TUBB4A—lymphoid tissue—skin cancer	0.000305	0.00756	CbGeAlD
Docetaxel—TUBB4A—female reproductive system—skin cancer	0.000294	0.00729	CbGeAlD
Docetaxel—TUBB4B—skin of body—skin cancer	0.000294	0.00728	CbGeAlD
Docetaxel—TUBB2B—female reproductive system—skin cancer	0.000285	0.00705	CbGeAlD
Docetaxel—MAP4—lymph node—skin cancer	0.000283	0.00701	CbGeAlD
Docetaxel—TUBB6—lymphoid tissue—skin cancer	0.000274	0.00678	CbGeAlD
Docetaxel—ABCC10—mammalian vulva—skin cancer	0.00027	0.00669	CbGeAlD
Docetaxel—TUBB4B—mammalian vulva—skin cancer	0.000268	0.00664	CbGeAlD
Docetaxel—TUBB2A—female reproductive system—skin cancer	0.000268	0.00663	CbGeAlD
Docetaxel—TUBB6—female reproductive system—skin cancer	0.000264	0.00654	CbGeAlD
Docetaxel—CYP1B1—connective tissue—skin cancer	0.000258	0.00639	CbGeAlD
Docetaxel—BCL2—lymph node—skin cancer	0.000257	0.00637	CbGeAlD
Docetaxel—EGFR—lymph node—skin cancer	0.000254	0.0063	CbGeAlD
Docetaxel—TUBB4A—head—skin cancer	0.000246	0.00609	CbGeAlD
Docetaxel—ABCC10—lymphoid tissue—skin cancer	0.00024	0.00594	CbGeAlD
Docetaxel—TUBB4B—lymphoid tissue—skin cancer	0.000238	0.0059	CbGeAlD
Docetaxel—TUBB2B—head—skin cancer	0.000238	0.00589	CbGeAlD
Docetaxel—CYP1B1—skin of body—skin cancer	0.000233	0.00577	CbGeAlD
Docetaxel—ABCC10—female reproductive system—skin cancer	0.000231	0.00573	CbGeAlD
Docetaxel—TUBB4B—female reproductive system—skin cancer	0.00023	0.00569	CbGeAlD
Docetaxel—TUBB2A—head—skin cancer	0.000224	0.00554	CbGeAlD
Docetaxel—MAP2—lymph node—skin cancer	0.000223	0.00552	CbGeAlD
Docetaxel—TUBB6—head—skin cancer	0.000221	0.00547	CbGeAlD
Docetaxel—TUBB4B—head—skin cancer	0.000192	0.00475	CbGeAlD
Docetaxel—ABCC1—mammalian vulva—skin cancer	0.000191	0.00473	CbGeAlD
Docetaxel—CYP1B1—lymphoid tissue—skin cancer	0.000189	0.00467	CbGeAlD
Docetaxel—ABCC2—female reproductive system—skin cancer	0.000186	0.0046	CbGeAlD
Docetaxel—ABCB1—blood vessel—skin cancer	0.000185	0.00457	CbGeAlD
Docetaxel—CYP1B1—female reproductive system—skin cancer	0.000182	0.0045	CbGeAlD
Docetaxel—TUBB4A—lymph node—skin cancer	0.000172	0.00427	CbGeAlD
Docetaxel—TUBB2B—lymph node—skin cancer	0.000166	0.00412	CbGeAlD
Docetaxel—ABCG2—mammalian vulva—skin cancer	0.000158	0.00392	CbGeAlD
Docetaxel—TUBB—lymph node—skin cancer	0.000158	0.0039	CbGeAlD
Docetaxel—TUBB2A—lymph node—skin cancer	0.000157	0.00388	CbGeAlD
Docetaxel—TUBB6—lymph node—skin cancer	0.000155	0.00383	CbGeAlD
Docetaxel—CYP1B1—head—skin cancer	0.000152	0.00376	CbGeAlD
Docetaxel—ABCC10—lymph node—skin cancer	0.000135	0.00335	CbGeAlD
Docetaxel—TUBB4B—lymph node—skin cancer	0.000134	0.00333	CbGeAlD
Docetaxel—Arthralgia—Imiquimod—skin cancer	0.000121	0.00118	CcSEcCtD
Docetaxel—Chest pain—Imiquimod—skin cancer	0.000121	0.00118	CcSEcCtD
Docetaxel—Myalgia—Imiquimod—skin cancer	0.000121	0.00118	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00012	0.00117	CcSEcCtD
Docetaxel—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.000119	0.00117	CcSEcCtD
Docetaxel—Dry skin—Fluorouracil—skin cancer	0.000119	0.00117	CcSEcCtD
Docetaxel—Dry mouth—Imiquimod—skin cancer	0.000118	0.00115	CcSEcCtD
Docetaxel—Decreased appetite—Vemurafenib—skin cancer	0.000118	0.00115	CcSEcCtD
Docetaxel—Stomatitis—Dactinomycin—skin cancer	0.000117	0.00115	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000117	0.00115	CcSEcCtD
Docetaxel—Fatigue—Vemurafenib—skin cancer	0.000117	0.00114	CcSEcCtD
Docetaxel—Haemoglobin—Bleomycin—skin cancer	0.000116	0.00114	CcSEcCtD
Docetaxel—Nasopharyngitis—Fluorouracil—skin cancer	0.000116	0.00114	CcSEcCtD
Docetaxel—Constipation—Vemurafenib—skin cancer	0.000116	0.00113	CcSEcCtD
Docetaxel—Pancytopenia—Temozolomide—skin cancer	0.000116	0.00113	CcSEcCtD
Docetaxel—Oedema—Imiquimod—skin cancer	0.000116	0.00113	CcSEcCtD
Docetaxel—Haemorrhage—Bleomycin—skin cancer	0.000116	0.00113	CcSEcCtD
Docetaxel—Hypoaesthesia—Bleomycin—skin cancer	0.000115	0.00113	CcSEcCtD
Docetaxel—Infection—Imiquimod—skin cancer	0.000115	0.00112	CcSEcCtD
Docetaxel—Neutropenia—Temozolomide—skin cancer	0.000114	0.00111	CcSEcCtD
Docetaxel—Shock—Imiquimod—skin cancer	0.000114	0.00111	CcSEcCtD
Docetaxel—Nervous system disorder—Imiquimod—skin cancer	0.000114	0.00111	CcSEcCtD
Docetaxel—Tachycardia—Imiquimod—skin cancer	0.000113	0.0011	CcSEcCtD
Docetaxel—Skin disorder—Imiquimod—skin cancer	0.000113	0.0011	CcSEcCtD
Docetaxel—Dysphagia—Fluorouracil—skin cancer	0.000113	0.0011	CcSEcCtD
Docetaxel—Agranulocytosis—Dactinomycin—skin cancer	0.000112	0.0011	CcSEcCtD
Docetaxel—Weight increased—Temozolomide—skin cancer	0.000111	0.00109	CcSEcCtD
Docetaxel—Weight decreased—Temozolomide—skin cancer	0.00011	0.00108	CcSEcCtD
Docetaxel—Anorexia—Imiquimod—skin cancer	0.00011	0.00108	CcSEcCtD
Docetaxel—Angina pectoris—Fluorouracil—skin cancer	0.00011	0.00107	CcSEcCtD
Docetaxel—Pneumonia—Temozolomide—skin cancer	0.00011	0.00107	CcSEcCtD
Docetaxel—Infestation—Temozolomide—skin cancer	0.000109	0.00106	CcSEcCtD
Docetaxel—Infestation NOS—Temozolomide—skin cancer	0.000109	0.00106	CcSEcCtD
Docetaxel—ABCC2—lymph node—skin cancer	0.000109	0.00269	CbGeAlD
Docetaxel—Hepatitis—Dactinomycin—skin cancer	0.000108	0.00106	CcSEcCtD
Docetaxel—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000108	0.00105	CcSEcCtD
Docetaxel—Flushing—Bleomycin—skin cancer	0.000108	0.00105	CcSEcCtD
Docetaxel—Body temperature increased—Vemurafenib—skin cancer	0.000107	0.00105	CcSEcCtD
Docetaxel—Pharyngitis—Dactinomycin—skin cancer	0.000107	0.00105	CcSEcCtD
Docetaxel—Pancytopenia—Fluorouracil—skin cancer	0.000107	0.00104	CcSEcCtD
Docetaxel—Neuropathy peripheral—Temozolomide—skin cancer	0.000107	0.00104	CcSEcCtD
Docetaxel—CYP1B1—lymph node—skin cancer	0.000106	0.00264	CbGeAlD
Docetaxel—Stomatitis—Temozolomide—skin cancer	0.000106	0.00104	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000106	0.00103	CcSEcCtD
Docetaxel—Insomnia—Imiquimod—skin cancer	0.000105	0.00102	CcSEcCtD
Docetaxel—Paraesthesia—Imiquimod—skin cancer	0.000104	0.00102	CcSEcCtD
Docetaxel—Chills—Bleomycin—skin cancer	0.000104	0.00102	CcSEcCtD
Docetaxel—Dyspnoea—Imiquimod—skin cancer	0.000103	0.00101	CcSEcCtD
Docetaxel—Somnolence—Imiquimod—skin cancer	0.000103	0.00101	CcSEcCtD
Docetaxel—Hepatobiliary disease—Temozolomide—skin cancer	0.000103	0.00101	CcSEcCtD
Docetaxel—Alopecia—Bleomycin—skin cancer	0.000102	0.001	CcSEcCtD
Docetaxel—Erythema multiforme—Dactinomycin—skin cancer	0.000102	0.000998	CcSEcCtD
Docetaxel—Dyspepsia—Imiquimod—skin cancer	0.000102	0.000996	CcSEcCtD
Docetaxel—Pneumonia—Fluorouracil—skin cancer	0.000101	0.000985	CcSEcCtD
Docetaxel—Erythema—Bleomycin—skin cancer	0.000101	0.000985	CcSEcCtD
Docetaxel—Decreased appetite—Imiquimod—skin cancer	0.000101	0.000984	CcSEcCtD
Docetaxel—Infestation—Fluorouracil—skin cancer	0.0001	0.00098	CcSEcCtD
Docetaxel—Infestation NOS—Fluorouracil—skin cancer	0.0001	0.00098	CcSEcCtD
Docetaxel—Flushing—Dactinomycin—skin cancer	0.0001	0.000979	CcSEcCtD
Docetaxel—Hypersensitivity—Vemurafenib—skin cancer	0.0001	0.000977	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Imiquimod—skin cancer	0.0001	0.000977	CcSEcCtD
Docetaxel—Fatigue—Imiquimod—skin cancer	9.99e-05	0.000975	CcSEcCtD
Docetaxel—Pain—Imiquimod—skin cancer	9.91e-05	0.000968	CcSEcCtD
Docetaxel—Acute coronary syndrome—Fluorouracil—skin cancer	9.89e-05	0.000966	CcSEcCtD
Docetaxel—Neuropathy peripheral—Fluorouracil—skin cancer	9.84e-05	0.00096	CcSEcCtD
Docetaxel—Myocardial infarction—Fluorouracil—skin cancer	9.84e-05	0.00096	CcSEcCtD
Docetaxel—Haemoglobin—Temozolomide—skin cancer	9.83e-05	0.000959	CcSEcCtD
Docetaxel—Stomatitis—Fluorouracil—skin cancer	9.78e-05	0.000955	CcSEcCtD
Docetaxel—Haemorrhage—Temozolomide—skin cancer	9.78e-05	0.000954	CcSEcCtD
Docetaxel—Hepatitis—Temozolomide—skin cancer	9.78e-05	0.000954	CcSEcCtD
Docetaxel—Conjunctivitis—Fluorouracil—skin cancer	9.75e-05	0.000952	CcSEcCtD
Docetaxel—Asthenia—Vemurafenib—skin cancer	9.75e-05	0.000952	CcSEcCtD
Docetaxel—Hypoaesthesia—Temozolomide—skin cancer	9.73e-05	0.00095	CcSEcCtD
Docetaxel—Pharyngitis—Temozolomide—skin cancer	9.7e-05	0.000947	CcSEcCtD
Docetaxel—Chills—Dactinomycin—skin cancer	9.7e-05	0.000947	CcSEcCtD
Docetaxel—Urinary tract disorder—Temozolomide—skin cancer	9.65e-05	0.000943	CcSEcCtD
Docetaxel—Oedema peripheral—Temozolomide—skin cancer	9.63e-05	0.00094	CcSEcCtD
Docetaxel—Pruritus—Vemurafenib—skin cancer	9.61e-05	0.000939	CcSEcCtD
Docetaxel—Connective tissue disorder—Temozolomide—skin cancer	9.61e-05	0.000938	CcSEcCtD
Docetaxel—Urethral disorder—Temozolomide—skin cancer	9.58e-05	0.000936	CcSEcCtD
Docetaxel—ABCC1—lymph node—skin cancer	9.57e-05	0.00237	CbGeAlD
Docetaxel—Alopecia—Dactinomycin—skin cancer	9.55e-05	0.000932	CcSEcCtD
Docetaxel—Feeling abnormal—Imiquimod—skin cancer	9.55e-05	0.000932	CcSEcCtD
Docetaxel—Gastrointestinal pain—Imiquimod—skin cancer	9.48e-05	0.000925	CcSEcCtD
Docetaxel—Epistaxis—Fluorouracil—skin cancer	9.46e-05	0.000924	CcSEcCtD
Docetaxel—CYP3A4—female reproductive system—skin cancer	9.43e-05	0.00234	CbGeAlD
Docetaxel—Visual impairment—Temozolomide—skin cancer	9.42e-05	0.00092	CcSEcCtD
Docetaxel—Erythema—Dactinomycin—skin cancer	9.41e-05	0.000919	CcSEcCtD
Docetaxel—Agranulocytosis—Fluorouracil—skin cancer	9.36e-05	0.000914	CcSEcCtD
Docetaxel—Anaemia—Bleomycin—skin cancer	9.32e-05	0.00091	CcSEcCtD
Docetaxel—Diarrhoea—Vemurafenib—skin cancer	9.3e-05	0.000908	CcSEcCtD
Docetaxel—Erythema multiforme—Temozolomide—skin cancer	9.24e-05	0.000902	CcSEcCtD
Docetaxel—Body temperature increased—Imiquimod—skin cancer	9.16e-05	0.000894	CcSEcCtD
Docetaxel—Abdominal pain—Imiquimod—skin cancer	9.16e-05	0.000894	CcSEcCtD
Docetaxel—Eye disorder—Temozolomide—skin cancer	9.14e-05	0.000892	CcSEcCtD
Docetaxel—Flushing—Temozolomide—skin cancer	9.07e-05	0.000886	CcSEcCtD
Docetaxel—Cardiac disorder—Temozolomide—skin cancer	9.07e-05	0.000886	CcSEcCtD
Docetaxel—Haemoglobin—Fluorouracil—skin cancer	9.05e-05	0.000884	CcSEcCtD
Docetaxel—Leukopenia—Bleomycin—skin cancer	9.03e-05	0.000882	CcSEcCtD
Docetaxel—Rhinitis—Fluorouracil—skin cancer	9.03e-05	0.000882	CcSEcCtD
Docetaxel—Haemorrhage—Fluorouracil—skin cancer	9.01e-05	0.000879	CcSEcCtD
Docetaxel—ABCB1—epithelium—skin cancer	8.99e-05	0.00223	CbGeAlD
Docetaxel—Dizziness—Vemurafenib—skin cancer	8.99e-05	0.000877	CcSEcCtD
Docetaxel—Hypoaesthesia—Fluorouracil—skin cancer	8.96e-05	0.000875	CcSEcCtD
Docetaxel—Pharyngitis—Fluorouracil—skin cancer	8.94e-05	0.000873	CcSEcCtD
Docetaxel—Angiopathy—Temozolomide—skin cancer	8.87e-05	0.000866	CcSEcCtD
Docetaxel—Immune system disorder—Temozolomide—skin cancer	8.83e-05	0.000862	CcSEcCtD
Docetaxel—Mediastinal disorder—Temozolomide—skin cancer	8.81e-05	0.00086	CcSEcCtD
Docetaxel—Cough—Bleomycin—skin cancer	8.8e-05	0.000859	CcSEcCtD
Docetaxel—Chills—Temozolomide—skin cancer	8.77e-05	0.000856	CcSEcCtD
Docetaxel—Anaemia—Dactinomycin—skin cancer	8.7e-05	0.000849	CcSEcCtD
Docetaxel—Vomiting—Vemurafenib—skin cancer	8.64e-05	0.000844	CcSEcCtD
Docetaxel—Alopecia—Temozolomide—skin cancer	8.64e-05	0.000843	CcSEcCtD
Docetaxel—Chest pain—Bleomycin—skin cancer	8.59e-05	0.000839	CcSEcCtD
Docetaxel—Myalgia—Bleomycin—skin cancer	8.59e-05	0.000839	CcSEcCtD
Docetaxel—Rash—Vemurafenib—skin cancer	8.57e-05	0.000837	CcSEcCtD
Docetaxel—Mental disorder—Temozolomide—skin cancer	8.56e-05	0.000836	CcSEcCtD
Docetaxel—Dermatitis—Vemurafenib—skin cancer	8.56e-05	0.000836	CcSEcCtD
Docetaxel—Hypersensitivity—Imiquimod—skin cancer	8.54e-05	0.000834	CcSEcCtD
Docetaxel—Headache—Vemurafenib—skin cancer	8.51e-05	0.000831	CcSEcCtD
Docetaxel—Erythema—Temozolomide—skin cancer	8.51e-05	0.000831	CcSEcCtD
Docetaxel—Malnutrition—Temozolomide—skin cancer	8.51e-05	0.000831	CcSEcCtD
Docetaxel—Leukopenia—Dactinomycin—skin cancer	8.42e-05	0.000822	CcSEcCtD
Docetaxel—Dysgeusia—Temozolomide—skin cancer	8.33e-05	0.000814	CcSEcCtD
Docetaxel—Asthenia—Imiquimod—skin cancer	8.32e-05	0.000812	CcSEcCtD
Docetaxel—Confusional state—Bleomycin—skin cancer	8.3e-05	0.00081	CcSEcCtD
Docetaxel—Anaphylactic shock—Bleomycin—skin cancer	8.23e-05	0.000804	CcSEcCtD
Docetaxel—Oedema—Bleomycin—skin cancer	8.23e-05	0.000804	CcSEcCtD
Docetaxel—Back pain—Temozolomide—skin cancer	8.23e-05	0.000804	CcSEcCtD
Docetaxel—Pruritus—Imiquimod—skin cancer	8.2e-05	0.000801	CcSEcCtD
Docetaxel—Infection—Bleomycin—skin cancer	8.18e-05	0.000799	CcSEcCtD
Docetaxel—Nausea—Vemurafenib—skin cancer	8.07e-05	0.000788	CcSEcCtD
Docetaxel—Thrombocytopenia—Bleomycin—skin cancer	8.06e-05	0.000787	CcSEcCtD
Docetaxel—Arrhythmia—Fluorouracil—skin cancer	8.05e-05	0.000786	CcSEcCtD
Docetaxel—Myalgia—Dactinomycin—skin cancer	8.01e-05	0.000782	CcSEcCtD
Docetaxel—Alopecia—Fluorouracil—skin cancer	7.96e-05	0.000777	CcSEcCtD
Docetaxel—Diarrhoea—Imiquimod—skin cancer	7.93e-05	0.000774	CcSEcCtD
Docetaxel—ABCG2—lymph node—skin cancer	7.92e-05	0.00196	CbGeAlD
Docetaxel—Anaemia—Temozolomide—skin cancer	7.87e-05	0.000768	CcSEcCtD
Docetaxel—Anorexia—Bleomycin—skin cancer	7.85e-05	0.000766	CcSEcCtD
Docetaxel—Erythema—Fluorouracil—skin cancer	7.84e-05	0.000765	CcSEcCtD
Docetaxel—ABCB1—mammalian vulva—skin cancer	7.8e-05	0.00193	CbGeAlD
Docetaxel—Hypotension—Bleomycin—skin cancer	7.69e-05	0.000751	CcSEcCtD
Docetaxel—Oedema—Dactinomycin—skin cancer	7.68e-05	0.00075	CcSEcCtD
Docetaxel—Dizziness—Imiquimod—skin cancer	7.66e-05	0.000748	CcSEcCtD
Docetaxel—Infection—Dactinomycin—skin cancer	7.63e-05	0.000745	CcSEcCtD
Docetaxel—Leukopenia—Temozolomide—skin cancer	7.62e-05	0.000744	CcSEcCtD
Docetaxel—Palpitations—Temozolomide—skin cancer	7.52e-05	0.000734	CcSEcCtD
Docetaxel—Thrombocytopenia—Dactinomycin—skin cancer	7.52e-05	0.000734	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Bleomycin—skin cancer	7.5e-05	0.000732	CcSEcCtD
Docetaxel—Cough—Temozolomide—skin cancer	7.43e-05	0.000725	CcSEcCtD
Docetaxel—Paraesthesia—Bleomycin—skin cancer	7.39e-05	0.000722	CcSEcCtD
Docetaxel—Convulsion—Temozolomide—skin cancer	7.37e-05	0.00072	CcSEcCtD
Docetaxel—Vomiting—Imiquimod—skin cancer	7.37e-05	0.000719	CcSEcCtD
Docetaxel—Hypertension—Temozolomide—skin cancer	7.35e-05	0.000717	CcSEcCtD
Docetaxel—Dyspnoea—Bleomycin—skin cancer	7.34e-05	0.000717	CcSEcCtD
Docetaxel—Anorexia—Dactinomycin—skin cancer	7.32e-05	0.000715	CcSEcCtD
Docetaxel—Rash—Imiquimod—skin cancer	7.31e-05	0.000713	CcSEcCtD
Docetaxel—Dermatitis—Imiquimod—skin cancer	7.3e-05	0.000713	CcSEcCtD
Docetaxel—Headache—Imiquimod—skin cancer	7.26e-05	0.000709	CcSEcCtD
Docetaxel—Anaemia—Fluorouracil—skin cancer	7.25e-05	0.000708	CcSEcCtD
Docetaxel—Myalgia—Temozolomide—skin cancer	7.25e-05	0.000707	CcSEcCtD
Docetaxel—Arthralgia—Temozolomide—skin cancer	7.25e-05	0.000707	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	7.2e-05	0.000702	CcSEcCtD
Docetaxel—Decreased appetite—Bleomycin—skin cancer	7.16e-05	0.000699	CcSEcCtD
Docetaxel—Dry mouth—Temozolomide—skin cancer	7.09e-05	0.000692	CcSEcCtD
Docetaxel—Pain—Bleomycin—skin cancer	7.04e-05	0.000687	CcSEcCtD
Docetaxel—Leukopenia—Fluorouracil—skin cancer	7.02e-05	0.000685	CcSEcCtD
Docetaxel—Confusional state—Temozolomide—skin cancer	7e-05	0.000684	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Dactinomycin—skin cancer	7e-05	0.000683	CcSEcCtD
Docetaxel—Oedema—Temozolomide—skin cancer	6.95e-05	0.000678	CcSEcCtD
Docetaxel—Anaphylactic shock—Temozolomide—skin cancer	6.95e-05	0.000678	CcSEcCtD
Docetaxel—ABCB1—lymphoid tissue—skin cancer	6.92e-05	0.00171	CbGeAlD
Docetaxel—Infection—Temozolomide—skin cancer	6.9e-05	0.000674	CcSEcCtD
Docetaxel—Nausea—Imiquimod—skin cancer	6.88e-05	0.000672	CcSEcCtD
Docetaxel—Nervous system disorder—Temozolomide—skin cancer	6.81e-05	0.000665	CcSEcCtD
Docetaxel—Thrombocytopenia—Temozolomide—skin cancer	6.8e-05	0.000664	CcSEcCtD
Docetaxel—Convulsion—Fluorouracil—skin cancer	6.79e-05	0.000663	CcSEcCtD
Docetaxel—Feeling abnormal—Bleomycin—skin cancer	6.78e-05	0.000662	CcSEcCtD
Docetaxel—Skin disorder—Temozolomide—skin cancer	6.75e-05	0.000659	CcSEcCtD
Docetaxel—ABCB1—female reproductive system—skin cancer	6.68e-05	0.00165	CbGeAlD
Docetaxel—Chest pain—Fluorouracil—skin cancer	6.68e-05	0.000652	CcSEcCtD
Docetaxel—Myalgia—Fluorouracil—skin cancer	6.68e-05	0.000652	CcSEcCtD
Docetaxel—Decreased appetite—Dactinomycin—skin cancer	6.68e-05	0.000652	CcSEcCtD
Docetaxel—Fatigue—Dactinomycin—skin cancer	6.62e-05	0.000646	CcSEcCtD
Docetaxel—Anorexia—Temozolomide—skin cancer	6.62e-05	0.000646	CcSEcCtD
Docetaxel—Pain—Dactinomycin—skin cancer	6.57e-05	0.000641	CcSEcCtD
Docetaxel—Body temperature increased—Bleomycin—skin cancer	6.51e-05	0.000635	CcSEcCtD
Docetaxel—Confusional state—Fluorouracil—skin cancer	6.45e-05	0.00063	CcSEcCtD
Docetaxel—Anaphylactic shock—Fluorouracil—skin cancer	6.4e-05	0.000625	CcSEcCtD
Docetaxel—Oedema—Fluorouracil—skin cancer	6.4e-05	0.000625	CcSEcCtD
Docetaxel—Infection—Fluorouracil—skin cancer	6.36e-05	0.000621	CcSEcCtD
Docetaxel—Feeling abnormal—Dactinomycin—skin cancer	6.33e-05	0.000618	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Temozolomide—skin cancer	6.33e-05	0.000618	CcSEcCtD
Docetaxel—Insomnia—Temozolomide—skin cancer	6.28e-05	0.000613	CcSEcCtD
Docetaxel—Gastrointestinal pain—Dactinomycin—skin cancer	6.28e-05	0.000613	CcSEcCtD
Docetaxel—Nervous system disorder—Fluorouracil—skin cancer	6.28e-05	0.000613	CcSEcCtD
Docetaxel—Thrombocytopenia—Fluorouracil—skin cancer	6.27e-05	0.000612	CcSEcCtD
Docetaxel—Tachycardia—Fluorouracil—skin cancer	6.25e-05	0.00061	CcSEcCtD
Docetaxel—Paraesthesia—Temozolomide—skin cancer	6.24e-05	0.000609	CcSEcCtD
Docetaxel—Dyspnoea—Temozolomide—skin cancer	6.19e-05	0.000605	CcSEcCtD
Docetaxel—Somnolence—Temozolomide—skin cancer	6.17e-05	0.000603	CcSEcCtD
Docetaxel—Dyspepsia—Temozolomide—skin cancer	6.11e-05	0.000597	CcSEcCtD
Docetaxel—Anorexia—Fluorouracil—skin cancer	6.1e-05	0.000596	CcSEcCtD
Docetaxel—Abdominal pain—Dactinomycin—skin cancer	6.07e-05	0.000593	CcSEcCtD
Docetaxel—Body temperature increased—Dactinomycin—skin cancer	6.07e-05	0.000593	CcSEcCtD
Docetaxel—Hypersensitivity—Bleomycin—skin cancer	6.07e-05	0.000592	CcSEcCtD
Docetaxel—Decreased appetite—Temozolomide—skin cancer	6.04e-05	0.000589	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Temozolomide—skin cancer	6e-05	0.000585	CcSEcCtD
Docetaxel—Fatigue—Temozolomide—skin cancer	5.99e-05	0.000585	CcSEcCtD
Docetaxel—Hypotension—Fluorouracil—skin cancer	5.98e-05	0.000584	CcSEcCtD
Docetaxel—Constipation—Temozolomide—skin cancer	5.94e-05	0.00058	CcSEcCtD
Docetaxel—Pain—Temozolomide—skin cancer	5.94e-05	0.00058	CcSEcCtD
Docetaxel—Asthenia—Bleomycin—skin cancer	5.91e-05	0.000577	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Fluorouracil—skin cancer	5.83e-05	0.000569	CcSEcCtD
Docetaxel—Pruritus—Bleomycin—skin cancer	5.83e-05	0.000569	CcSEcCtD
Docetaxel—Insomnia—Fluorouracil—skin cancer	5.79e-05	0.000565	CcSEcCtD
Docetaxel—Paraesthesia—Fluorouracil—skin cancer	5.75e-05	0.000561	CcSEcCtD
Docetaxel—Feeling abnormal—Temozolomide—skin cancer	5.72e-05	0.000559	CcSEcCtD
Docetaxel—Dyspnoea—Fluorouracil—skin cancer	5.71e-05	0.000557	CcSEcCtD
Docetaxel—Somnolence—Fluorouracil—skin cancer	5.69e-05	0.000555	CcSEcCtD
Docetaxel—Gastrointestinal pain—Temozolomide—skin cancer	5.68e-05	0.000554	CcSEcCtD
Docetaxel—Hypersensitivity—Dactinomycin—skin cancer	5.66e-05	0.000552	CcSEcCtD
Docetaxel—Dyspepsia—Fluorouracil—skin cancer	5.63e-05	0.00055	CcSEcCtD
Docetaxel—ABCB1—head—skin cancer	5.58e-05	0.00138	CbGeAlD
Docetaxel—Decreased appetite—Fluorouracil—skin cancer	5.56e-05	0.000543	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Fluorouracil—skin cancer	5.52e-05	0.000539	CcSEcCtD
Docetaxel—Asthenia—Dactinomycin—skin cancer	5.51e-05	0.000538	CcSEcCtD
Docetaxel—Body temperature increased—Temozolomide—skin cancer	5.49e-05	0.000536	CcSEcCtD
Docetaxel—Abdominal pain—Temozolomide—skin cancer	5.49e-05	0.000536	CcSEcCtD
Docetaxel—Pain—Fluorouracil—skin cancer	5.47e-05	0.000534	CcSEcCtD
Docetaxel—Feeling abnormal—Fluorouracil—skin cancer	5.27e-05	0.000515	CcSEcCtD
Docetaxel—Diarrhoea—Dactinomycin—skin cancer	5.25e-05	0.000513	CcSEcCtD
Docetaxel—Vomiting—Bleomycin—skin cancer	5.23e-05	0.000511	CcSEcCtD
Docetaxel—Rash—Bleomycin—skin cancer	5.19e-05	0.000507	CcSEcCtD
Docetaxel—Dermatitis—Bleomycin—skin cancer	5.19e-05	0.000506	CcSEcCtD
Docetaxel—Hypersensitivity—Temozolomide—skin cancer	5.12e-05	0.0005	CcSEcCtD
Docetaxel—Body temperature increased—Fluorouracil—skin cancer	5.06e-05	0.000494	CcSEcCtD
Docetaxel—Asthenia—Temozolomide—skin cancer	4.98e-05	0.000486	CcSEcCtD
Docetaxel—Pruritus—Temozolomide—skin cancer	4.91e-05	0.00048	CcSEcCtD
Docetaxel—Nausea—Bleomycin—skin cancer	4.89e-05	0.000477	CcSEcCtD
Docetaxel—Vomiting—Dactinomycin—skin cancer	4.88e-05	0.000477	CcSEcCtD
Docetaxel—Rash—Dactinomycin—skin cancer	4.84e-05	0.000473	CcSEcCtD
Docetaxel—Diarrhoea—Temozolomide—skin cancer	4.75e-05	0.000464	CcSEcCtD
Docetaxel—Hypersensitivity—Fluorouracil—skin cancer	4.71e-05	0.00046	CcSEcCtD
Docetaxel—Dizziness—Temozolomide—skin cancer	4.59e-05	0.000448	CcSEcCtD
Docetaxel—Nausea—Dactinomycin—skin cancer	4.56e-05	0.000445	CcSEcCtD
Docetaxel—Pruritus—Fluorouracil—skin cancer	4.53e-05	0.000442	CcSEcCtD
Docetaxel—Vomiting—Temozolomide—skin cancer	4.42e-05	0.000431	CcSEcCtD
Docetaxel—Rash—Temozolomide—skin cancer	4.38e-05	0.000428	CcSEcCtD
Docetaxel—Diarrhoea—Fluorouracil—skin cancer	4.38e-05	0.000427	CcSEcCtD
Docetaxel—Dermatitis—Temozolomide—skin cancer	4.38e-05	0.000427	CcSEcCtD
Docetaxel—Headache—Temozolomide—skin cancer	4.35e-05	0.000425	CcSEcCtD
Docetaxel—Dizziness—Fluorouracil—skin cancer	4.23e-05	0.000413	CcSEcCtD
Docetaxel—Nausea—Temozolomide—skin cancer	4.13e-05	0.000403	CcSEcCtD
Docetaxel—Vomiting—Fluorouracil—skin cancer	4.07e-05	0.000397	CcSEcCtD
Docetaxel—Rash—Fluorouracil—skin cancer	4.03e-05	0.000394	CcSEcCtD
Docetaxel—Dermatitis—Fluorouracil—skin cancer	4.03e-05	0.000394	CcSEcCtD
Docetaxel—Headache—Fluorouracil—skin cancer	4.01e-05	0.000391	CcSEcCtD
Docetaxel—ABCB1—lymph node—skin cancer	3.91e-05	0.000968	CbGeAlD
Docetaxel—Nausea—Fluorouracil—skin cancer	3.8e-05	0.000371	CcSEcCtD
Docetaxel—TUBB—Cell Cycle, Mitotic—CDKN2A—skin cancer	2.18e-05	0.000671	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.17e-05	0.00067	CbGpPWpGaD
Docetaxel—GHRHR—Signaling by GPCR—NRAS—skin cancer	2.16e-05	0.000667	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle, Mitotic—CDK4—skin cancer	2.16e-05	0.000665	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—TERT—skin cancer	2.16e-05	0.000665	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways in Glioblastoma—HRAS—skin cancer	2.15e-05	0.000662	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—CDK4—skin cancer	2.11e-05	0.000651	CbGpPWpGaD
Docetaxel—EGFR—Immune System—TLR7—skin cancer	2.1e-05	0.000646	CbGpPWpGaD
Docetaxel—EGFR—ErbB1 downstream signaling—KRAS—skin cancer	2.07e-05	0.000639	CbGpPWpGaD
Docetaxel—NR1I2—Gene Expression—ERCC2—skin cancer	2.06e-05	0.000634	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—MC1R—skin cancer	2.04e-05	0.000627	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—BRAF—skin cancer	2.03e-05	0.000627	CbGpPWpGaD
Docetaxel—KIF11—Immune System—KRAS—skin cancer	2e-05	0.000617	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PLIN2—skin cancer	1.98e-05	0.000612	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle—CDKN2A—skin cancer	1.95e-05	0.0006	CbGpPWpGaD
Docetaxel—BCL2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.93e-05	0.000595	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—CDK4—skin cancer	1.93e-05	0.000595	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	1.92e-05	0.000591	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PLIN2—skin cancer	1.92e-05	0.000591	CbGpPWpGaD
Docetaxel—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.91e-05	0.000589	CbGpPWpGaD
Docetaxel—ABCC1—Disease—CSPG4—skin cancer	1.91e-05	0.000589	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—NRAS—skin cancer	1.9e-05	0.000587	CbGpPWpGaD
Docetaxel—GHRHR—Signaling by GPCR—KRAS—skin cancer	1.86e-05	0.000574	CbGpPWpGaD
Docetaxel—BCL2—Focal Adhesion—HRAS—skin cancer	1.86e-05	0.000572	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—FOXO4—skin cancer	1.86e-05	0.000572	CbGpPWpGaD
Docetaxel—BCL2—Immune System—FOXO4—skin cancer	1.83e-05	0.000563	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling of activated FGFR—NRAS—skin cancer	1.82e-05	0.000561	CbGpPWpGaD
Docetaxel—EGFR—Regulation of Actin Cytoskeleton—NRAS—skin cancer	1.82e-05	0.000561	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle, Mitotic—CDKN2A—skin cancer	1.81e-05	0.000556	CbGpPWpGaD
Docetaxel—EGFR—Disease—CSPG4—skin cancer	1.8e-05	0.000555	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB4—NRAS—skin cancer	1.79e-05	0.000552	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—FOXO4—skin cancer	1.78e-05	0.000549	CbGpPWpGaD
Docetaxel—EGFR—ErbB1 downstream signaling—HRAS—skin cancer	1.76e-05	0.000543	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PLIN2—skin cancer	1.75e-05	0.000538	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PLIN2—skin cancer	1.73e-05	0.000533	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—BRAF—skin cancer	1.72e-05	0.00053	CbGpPWpGaD
Docetaxel—EGFR—Downstream signal transduction—NRAS—skin cancer	1.71e-05	0.000528	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—NRAS—skin cancer	1.7e-05	0.000525	CbGpPWpGaD
Docetaxel—KIF11—Immune System—HRAS—skin cancer	1.7e-05	0.000524	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB2—NRAS—skin cancer	1.7e-05	0.000522	CbGpPWpGaD
Docetaxel—EGFR—DAP12 signaling—NRAS—skin cancer	1.69e-05	0.00052	CbGpPWpGaD
Docetaxel—EGFR—Spinal Cord Injury—TP53—skin cancer	1.68e-05	0.000517	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PTCH2—skin cancer	1.66e-05	0.000513	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	1.66e-05	0.000512	CbGpPWpGaD
Docetaxel—EGFR—MAPK Signaling Pathway—NRAS—skin cancer	1.66e-05	0.00051	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle, Mitotic—CDKN2A—skin cancer	1.65e-05	0.000509	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—KRAS—skin cancer	1.64e-05	0.000505	CbGpPWpGaD
Docetaxel—KIF11—Immune System—IL6—skin cancer	1.63e-05	0.000502	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—CDKN2A—skin cancer	1.61e-05	0.000497	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—CSPG4—skin cancer	1.6e-05	0.000493	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	1.59e-05	0.000489	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—NRAS—skin cancer	1.59e-05	0.000489	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—NRAS—skin cancer	1.59e-05	0.000489	CbGpPWpGaD
Docetaxel—GHRHR—Signaling by GPCR—HRAS—skin cancer	1.58e-05	0.000488	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR—NRAS—skin cancer	1.57e-05	0.000485	CbGpPWpGaD
Docetaxel—EGFR—Regulation of Actin Cytoskeleton—KRAS—skin cancer	1.57e-05	0.000483	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling of activated FGFR—KRAS—skin cancer	1.57e-05	0.000483	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR in Cancer—NRAS—skin cancer	1.56e-05	0.00048	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—NRAS—skin cancer	1.55e-05	0.000478	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—KRAS—skin cancer	1.55e-05	0.000478	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—CSPG4—skin cancer	1.55e-05	0.000477	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB4—KRAS—skin cancer	1.54e-05	0.000475	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—ENO2—skin cancer	1.54e-05	0.000474	CbGpPWpGaD
Docetaxel—EGFR—Spinal Cord Injury—IL6—skin cancer	1.54e-05	0.000474	CbGpPWpGaD
Docetaxel—GHRHR—Signaling by GPCR—IL6—skin cancer	1.52e-05	0.000467	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—CDKN2A—skin cancer	1.48e-05	0.000455	CbGpPWpGaD
Docetaxel—EGFR—Downstream signal transduction—KRAS—skin cancer	1.47e-05	0.000454	CbGpPWpGaD
Docetaxel—EGFR—B Cell Activation—NRAS—skin cancer	1.47e-05	0.000453	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—KRAS—skin cancer	1.47e-05	0.000452	CbGpPWpGaD
Docetaxel—EGFR—EGF/EGFR Signaling Pathway—KRAS—skin cancer	1.47e-05	0.000452	CbGpPWpGaD
Docetaxel—EGFR—Direct p53 effectors—TP53—skin cancer	1.46e-05	0.000451	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB2—KRAS—skin cancer	1.46e-05	0.00045	CbGpPWpGaD
Docetaxel—EGFR—DAP12 signaling—KRAS—skin cancer	1.45e-05	0.000447	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—SHH—skin cancer	1.45e-05	0.000447	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	1.43e-05	0.000441	CbGpPWpGaD
Docetaxel—EGFR—MAPK Signaling Pathway—KRAS—skin cancer	1.42e-05	0.000439	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—CSPG4—skin cancer	1.41e-05	0.000434	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	1.41e-05	0.000433	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—CSPG4—skin cancer	1.4e-05	0.00043	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—HRAS—skin cancer	1.39e-05	0.000429	CbGpPWpGaD
Docetaxel—EGFR—Integrated Breast Cancer Pathway—TP53—skin cancer	1.38e-05	0.000425	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—PTCH1—skin cancer	1.38e-05	0.000424	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—SMO—skin cancer	1.38e-05	0.000424	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	1.37e-05	0.000421	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—KRAS—skin cancer	1.37e-05	0.000421	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—KRAS—skin cancer	1.37e-05	0.000421	CbGpPWpGaD
Docetaxel—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.36e-05	0.000419	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.36e-05	0.000418	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR—KRAS—skin cancer	1.35e-05	0.000417	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR in Cancer—KRAS—skin cancer	1.34e-05	0.000413	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—PTGER4—skin cancer	1.34e-05	0.000413	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—KRAS—skin cancer	1.34e-05	0.000412	CbGpPWpGaD
Docetaxel—EGFR—Signaling by SCF-KIT—IL6—skin cancer	1.33e-05	0.000411	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling of activated FGFR—HRAS—skin cancer	1.33e-05	0.000411	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB4—HRAS—skin cancer	1.31e-05	0.000404	CbGpPWpGaD
Docetaxel—ABCC1—Disease—ENO2—skin cancer	1.3e-05	0.0004	CbGpPWpGaD
Docetaxel—ABCC1—Disease—SHH—skin cancer	1.3e-05	0.0004	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.29e-05	0.000396	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—NRAS—skin cancer	1.28e-05	0.000394	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling of activated FGFR—IL6—skin cancer	1.28e-05	0.000393	CbGpPWpGaD
Docetaxel—EGFR—MAPK Signaling Pathway—TP53—skin cancer	1.27e-05	0.00039	CbGpPWpGaD
Docetaxel—EGFR—B Cell Activation—KRAS—skin cancer	1.26e-05	0.00039	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—GLI2—skin cancer	1.26e-05	0.000388	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—CDK4—skin cancer	1.26e-05	0.000387	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB4—IL6—skin cancer	1.26e-05	0.000387	CbGpPWpGaD
Docetaxel—EGFR—Downstream signal transduction—HRAS—skin cancer	1.25e-05	0.000386	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PLIN2—skin cancer	1.25e-05	0.000386	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—HRAS—skin cancer	1.25e-05	0.000384	CbGpPWpGaD
Docetaxel—EGFR—EGF/EGFR Signaling Pathway—HRAS—skin cancer	1.25e-05	0.000384	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB2—HRAS—skin cancer	1.24e-05	0.000382	CbGpPWpGaD
Docetaxel—EGFR—DAP12 signaling—HRAS—skin cancer	1.23e-05	0.00038	CbGpPWpGaD
Docetaxel—EGFR—Disease—SHH—skin cancer	1.22e-05	0.000377	CbGpPWpGaD
Docetaxel—EGFR—Disease—ENO2—skin cancer	1.22e-05	0.000377	CbGpPWpGaD
Docetaxel—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	1.22e-05	0.000375	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	1.21e-05	0.000373	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.2e-05	0.000371	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MC1R—skin cancer	1.2e-05	0.000371	CbGpPWpGaD
Docetaxel—EGFR—Downstream signal transduction—IL6—skin cancer	1.2e-05	0.000369	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR—IL6—skin cancer	1.19e-05	0.000368	CbGpPWpGaD
Docetaxel—EGFR—Signaling by ERBB2—IL6—skin cancer	1.19e-05	0.000366	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—GLI1—skin cancer	1.19e-05	0.000365	CbGpPWpGaD
Docetaxel—EGFR—DAP12 signaling—IL6—skin cancer	1.18e-05	0.000364	CbGpPWpGaD
Docetaxel—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.17e-05	0.00036	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—HRAS—skin cancer	1.16e-05	0.000358	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	1.16e-05	0.000358	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—HRAS—skin cancer	1.16e-05	0.000358	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR—HRAS—skin cancer	1.15e-05	0.000355	CbGpPWpGaD
Docetaxel—EGFR—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.14e-05	0.000352	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR in Cancer—HRAS—skin cancer	1.14e-05	0.000351	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—HRAS—skin cancer	1.14e-05	0.00035	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—SUFU—skin cancer	1.12e-05	0.000346	CbGpPWpGaD
Docetaxel—EGFR—Signaling by FGFR in disease—IL6—skin cancer	1.11e-05	0.000342	CbGpPWpGaD
Docetaxel—EGFR—DAP12 interactions—IL6—skin cancer	1.11e-05	0.000342	CbGpPWpGaD
Docetaxel—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	1.11e-05	0.000342	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR—IL6—skin cancer	1.1e-05	0.000339	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—KRAS—skin cancer	1.1e-05	0.000339	CbGpPWpGaD
Docetaxel—EGFR—Focal Adhesion—HRAS—skin cancer	1.1e-05	0.000338	CbGpPWpGaD
Docetaxel—EGFR—Signaling by EGFR in Cancer—IL6—skin cancer	1.09e-05	0.000336	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—ENO2—skin cancer	1.09e-05	0.000335	CbGpPWpGaD
Docetaxel—EGFR—Signaling by PDGF—IL6—skin cancer	1.09e-05	0.000335	CbGpPWpGaD
Docetaxel—TUBB—Cell Cycle—TP53—skin cancer	1.08e-05	0.000334	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—NRAS—skin cancer	1.08e-05	0.000333	CbGpPWpGaD
Docetaxel—EGFR—Immune System—FOXO4—skin cancer	1.08e-05	0.000333	CbGpPWpGaD
Docetaxel—EGFR—B Cell Activation—HRAS—skin cancer	1.07e-05	0.000331	CbGpPWpGaD
Docetaxel—ABCC1—Disease—FOXO4—skin cancer	1.06e-05	0.000326	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—ENO2—skin cancer	1.05e-05	0.000324	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—NRAS—skin cancer	1.04e-05	0.000321	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	1.03e-05	0.000317	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CSPG4—skin cancer	1.01e-05	0.000311	CbGpPWpGaD
Docetaxel—EGFR—Disease—FOXO4—skin cancer	9.98e-06	0.000307	CbGpPWpGaD
Docetaxel—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	9.94e-06	0.000306	CbGpPWpGaD
Docetaxel—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	9.85e-06	0.000303	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—NRAS—skin cancer	9.79e-06	0.000302	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—TP53—skin cancer	9.78e-06	0.000301	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	9.69e-06	0.000299	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—ENO2—skin cancer	9.57e-06	0.000295	CbGpPWpGaD
Docetaxel—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	9.51e-06	0.000293	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—ENO2—skin cancer	9.49e-06	0.000292	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PLIN2—skin cancer	9.44e-06	0.000291	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—HRAS—skin cancer	9.35e-06	0.000288	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—KRAS—skin cancer	9.31e-06	0.000287	CbGpPWpGaD
Docetaxel—TUBB4A—Cell Cycle—TP53—skin cancer	8.98e-06	0.000277	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—KRAS—skin cancer	8.98e-06	0.000277	CbGpPWpGaD
Docetaxel—GHRHR—Signaling Pathways—IL6—skin cancer	8.95e-06	0.000276	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—ERCC2—skin cancer	8.94e-06	0.000275	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—SHH—skin cancer	8.57e-06	0.000264	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—RASA1—skin cancer	8.52e-06	0.000262	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.51e-06	0.000262	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—KRAS—skin cancer	8.42e-06	0.00026	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.23e-06	0.000253	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—TP53—skin cancer	8.22e-06	0.000253	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—SMO—skin cancer	8.13e-06	0.00025	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PTCH1—skin cancer	8.13e-06	0.00025	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—HRAS—skin cancer	7.91e-06	0.000244	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PTGER4—skin cancer	7.91e-06	0.000244	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—HRAS—skin cancer	7.63e-06	0.000235	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CSPG4—skin cancer	7.61e-06	0.000235	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—IL6—skin cancer	7.57e-06	0.000233	CbGpPWpGaD
Docetaxel—ABCC1—Disease—ERCC2—skin cancer	7.54e-06	0.000232	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—IL6—skin cancer	7.31e-06	0.000225	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—HRAS—skin cancer	7.16e-06	0.000221	CbGpPWpGaD
Docetaxel—EGFR—Disease—ERCC2—skin cancer	7.11e-06	0.000219	CbGpPWpGaD
Docetaxel—ABCC1—Disease—TERT—skin cancer	7.07e-06	0.000218	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—FOXO4—skin cancer	6.99e-06	0.000215	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—NRAS—skin cancer	6.98e-06	0.000215	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ENO2—skin cancer	6.86e-06	0.000211	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—IL6—skin cancer	6.85e-06	0.000211	CbGpPWpGaD
Docetaxel—EGFR—Disease—TERT—skin cancer	6.66e-06	0.000205	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	6.49e-06	0.0002	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—ERCC2—skin cancer	6.32e-06	0.000195	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—NRAS—skin cancer	6.17e-06	0.00019	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—ERCC2—skin cancer	6.11e-06	0.000188	CbGpPWpGaD
Docetaxel—BCL2—Immune System—NRAS—skin cancer	6.08e-06	0.000187	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—KRAS—skin cancer	6.01e-06	0.000185	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—NRAS—skin cancer	5.92e-06	0.000182	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PLIN2—skin cancer	5.82e-06	0.000179	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.77e-06	0.000178	CbGpPWpGaD
Docetaxel—ABCC1—Disease—BRAF—skin cancer	5.6e-06	0.000173	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—ERCC2—skin cancer	5.56e-06	0.000171	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—ERCC2—skin cancer	5.51e-06	0.00017	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—PTGS2—skin cancer	5.36e-06	0.000165	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—KRAS—skin cancer	5.31e-06	0.000164	CbGpPWpGaD
Docetaxel—EGFR—Disease—BRAF—skin cancer	5.28e-06	0.000163	CbGpPWpGaD
Docetaxel—BCL2—Immune System—KRAS—skin cancer	5.23e-06	0.000161	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ENO2—skin cancer	5.17e-06	0.000159	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—HRAS—skin cancer	5.11e-06	0.000157	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—KRAS—skin cancer	5.1e-06	0.000157	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—IL6—skin cancer	4.89e-06	0.000151	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CSPG4—skin cancer	4.69e-06	0.000144	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TERT—skin cancer	4.67e-06	0.000144	CbGpPWpGaD
Docetaxel—ABCC1—Disease—PTGS2—skin cancer	4.52e-06	0.000139	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—HRAS—skin cancer	4.51e-06	0.000139	CbGpPWpGaD
Docetaxel—BCL2—Immune System—HRAS—skin cancer	4.45e-06	0.000137	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—HRAS—skin cancer	4.33e-06	0.000134	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—IL6—skin cancer	4.32e-06	0.000133	CbGpPWpGaD
Docetaxel—EGFR—Disease—PTGS2—skin cancer	4.26e-06	0.000131	CbGpPWpGaD
Docetaxel—BCL2—Immune System—IL6—skin cancer	4.25e-06	0.000131	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ERCC2—skin cancer	3.98e-06	0.000123	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—NRAS—skin cancer	3.93e-06	0.000121	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PTGS2—skin cancer	3.79e-06	0.000117	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—BRAF—skin cancer	3.7e-06	0.000114	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PTGS2—skin cancer	3.66e-06	0.000113	CbGpPWpGaD
Docetaxel—EGFR—Immune System—NRAS—skin cancer	3.59e-06	0.000111	CbGpPWpGaD
Docetaxel—ABCC1—Disease—NRAS—skin cancer	3.52e-06	0.000108	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—KRAS—skin cancer	3.38e-06	0.000104	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PTGS2—skin cancer	3.33e-06	0.000103	CbGpPWpGaD
Docetaxel—EGFR—Disease—NRAS—skin cancer	3.32e-06	0.000102	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PTGS2—skin cancer	3.3e-06	0.000102	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ENO2—skin cancer	3.19e-06	9.82e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—KRAS—skin cancer	3.09e-06	9.53e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—KRAS—skin cancer	3.03e-06	9.33e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ERCC2—skin cancer	3.01e-06	9.26e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—HRAS—skin cancer	2.88e-06	8.86e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—KRAS—skin cancer	2.85e-06	8.8e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—IL6—skin cancer	2.75e-06	8.48e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—HRAS—skin cancer	2.63e-06	8.1e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—HRAS—skin cancer	2.57e-06	7.93e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—IL6—skin cancer	2.52e-06	7.75e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—IL6—skin cancer	2.46e-06	7.59e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—HRAS—skin cancer	2.43e-06	7.48e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PTGS2—skin cancer	2.39e-06	7.36e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—NRAS—skin cancer	2.32e-06	7.16e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—IL6—skin cancer	2.32e-06	7.16e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—KRAS—skin cancer	2e-06	6.16e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ERCC2—skin cancer	1.85e-06	5.7e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PTGS2—skin cancer	1.8e-06	5.55e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TP53—skin cancer	1.78e-06	5.47e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—HRAS—skin cancer	1.7e-06	5.24e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—IL6—skin cancer	1.63e-06	5.01e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PTGS2—skin cancer	1.11e-06	3.42e-05	CbGpPWpGaD
